

Dopamine agonists in prolactinoma

Table S7. Drop out, adverse events and notes for included studies.

Study (Ref.nr.)	Drop out, n (total)	DA adverse effects
Schwetz (25)	0 (53)	-
Auriemma II (26)	0 (32)	-
Medic (31)	0 (20)	-
Pala (27)	9 ⁴ (28)	-
Barbosa (33)	14 ¹ (35)	Gastrointestinal intolerance (n=5).
Auriemma (5)	0 (61)	-
Ciresi (4)	0 (43)	-
Inancli (29)	0 (21)	-
Berinder (6)	1 ² (15)	-
Silva (8)	13 ³ (35)	-
Serri (7)	-	None
Yavuz (28)	0 (16)	Nausea, dizziness, sleep disturbances (n=14).
Doknic (30)	0 (23)	-
Iglesias (32)	0 (27)	-

(-) Not reported

¹ Ten patients were excluded due to their discontinuation of DA use because of irregular drug supply, two became pregnant, one did not complete the six-month sleep study, and one was submitted to transsphenoidal surgery due to a macroprolactinoma resistant to DA.

² Pregnancy

³ Ten patients were excluded due to their discontinuation of DA use because of irregular drug supply, two became pregnant and one was submitted to transsphenoidal surgery due to a macroprolactinoma resistant to DA.

⁴ Four women became pregnant, four women lost to follow-up, one man excluded (no reason given).

Dopamine agonists in prolactinoma